Paratek Pharmaceuticals Stock Total Debt
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
Paratek Pharmaceuticals fundamentals help investors to digest information that contributes to Paratek Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Paratek Stock. The fundamental analysis module provides a way to measure Paratek Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Paratek Pharmaceuticals stock.
Paratek |
Paratek Pharmaceuticals Company Total Debt Analysis
Paratek Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Paratek Pharmaceuticals Total Debt | 258.41 M |
Most of Paratek Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paratek Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Paratek Pharmaceuticals has a Total Debt of 258.41 M. This is 90.61% lower than that of the Pharmaceuticals sector and 20.44% lower than that of the Health Care industry. The total debt for all United States stocks is 95.14% higher than that of the company.
Paratek Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paratek Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics of similar companies.Paratek Pharmaceuticals is currently under evaluation in total debt category among its peers.
Paratek Fundamentals
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Shares Owned By Insiders | 11.70 % | |||
| Shares Owned By Institutions | 55.08 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X | |||
| Revenue | 150.79 M | |||
| Gross Profit | 99.39 M | |||
| EBITDA | (44.9 M) | |||
| Net Income | (63.57 M) | |||
| Cash And Equivalents | 57.01 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 258.41 M | |||
| Debt To Equity | 3.20 % | |||
| Current Ratio | 3.11 X | |||
| Book Value Per Share | (3.52) X | |||
| Cash Flow From Operations | (66.14 M) | |||
| Short Ratio | 6.74 X | |||
| Earnings Per Share | (1.11) X | |||
| Price To Earnings To Growth | (0.02) X | |||
| Target Price | 3.1 | |||
| Number Of Employees | 268 | |||
| Beta | 1.7 | |||
| Market Capitalization | 127.83 M | |||
| Total Asset | 172.54 M | |||
| Retained Earnings | (930.45 M) | |||
| Working Capital | 99.45 M | |||
| Current Asset | 127.46 M | |||
| Current Liabilities | 21.75 M | |||
| Z Score | -6.55 | |||
| Net Asset | 172.54 M |
About Paratek Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Paratek Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |